Troy, Jesse D.
Locke, Susan C.
Samsa, Greg P.
Feliciano, Joseph
Richhariya, Akshara
LeBlanc, Thomas W.
Funding for this research was provided by:
Seattle Genetics
Article History
Received: 11 April 2018
Accepted: 19 October 2018
First Online: 30 October 2018
Compliance with ethical standards
: Jesse Troy reports honoraria from GamidaCell, consulting fees from The EMMES Corporation, AegisCN, and The Community Data Roundtable; Thomas LeBlanc reports consulting fees from Amgen, Agios, AbbVie, CareVive, Celgene, Pfizer, Helsinn, Flatiron Health, Medtronic, Otsuka, Welvie, and Heron, grants from American Cancer Society, AstraZeneca, and Cambia Health Solutions. Jose Feliciano and Akshara Richhariya report equity ownership and employment at Seattle Genetics. Susan Locke and Greg Samsa have no disclosures to report.